HC Wainwright reiterates Neutral on Lipocine, $4 target
HC Wainwright & Co. reiterated a Neutral rating on Lipocine, setting a $4.00 price target. The target implies 81.0% upside versus the Sep 18 close of $2.21.
HC Wainwright & Co. reiterated a Neutral rating on Lipocine, setting a $4.00 price target. The target implies 81.0% upside versus the Sep 18 close of $2.21.